H.C. Wainwright维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价22美元
JonesTrading维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价45美元
eyepoint pharmaceuticals的目标股价维持在每股22.00美元,HC Wainwright & Co.继续保持。
eyepoint pharmaceuticals 分析师评级
JonesTrading维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价45美元
贝雅维持EyePoint Pharmaceuticals(EYPT.US)买入评级,下调目标价至33美元
JonesTrading维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价45美元
H.C. Wainwright维持EyePoint Pharmaceuticals(EYPT.US)买入评级,下调目标价至22美元
eyepoint pharmaceuticals被HC Wainwright & Co买入维持
eyepoint pharmaceuticals价格目标从30.00美元降至22.00美元,由HC Wainwright & Co.进行裁减。
TD Cowen维持EyePoint Pharmaceuticals(EYPT.US)买入评级,下调目标价至20美元
eyepoint pharmaceuticals:临床试验进展及有望的中期数据推动了买入评级
丰业银行维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价18美元
eyepoint pharmaceuticals被Chardan Capital维持为买入
eyepoint pharmaceuticals 分析师评级
第一资本维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价35美元
JonesTrading首予EyePoint Pharmaceuticals(EYPT.US)买入评级,目标价45美元
贝雅维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价38美元
H.C. Wainwright维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价30美元
eyepoint pharmaceuticals积极前景:DURAVYU的第3阶段LUGANO试验推动买入评级提升